Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 158 Jul 28 – Oct 25, 2026
- Disclosed funding
- $6B 122 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AB Athernal BioCompany profile Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges. Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges. | ~£700K | GrantUndisclosed | Biotech | United Kingdom | Investors | |
| E EthrisCompany profile Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms. Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms. | €30M | HERA Invest financingUndisclosed | Biotech | Germany | Investors | |
| CT Connecta TherapeuticsCompany profile Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome. Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome. | €3.1M | Clinical development financingUndisclosed | Biotech | Spain | Investors | |
| OB One BiosciencesCompany profile Single-cell tumour profiling for oncology teams and pharma and biotech partners, turning routine biopsy samples into clinical insights for treatment selection and drug development. Single-cell tumour profiling for oncology teams and pharma and biotech partners, turning routine biopsy samples into clinical insights for treatment selection and drug development. | €3.3M | i-Démo 5 grant (France 2030)Undisclosed | Biotech | France | Investors | |
| P PhagestackCompany profile A phage-discovery and development company that uses bacteriophage libraries, bioinformatics and machine learning to identify targeted solutions against bacterial strains. A phage-discovery and development company that uses bacteriophage libraries, bioinformatics and machine learning to identify targeted solutions against bacterial strains. | Undisclosed | NRW.BANK investmentUndisclosed | Biotech | Germany | Investors | |
| A AllogeneticsCompany profile Allogenetics is developing a one-time ex vivo gene therapy that modifies donor organs before transplantation, aiming to reduce immune rejection without suppressing the recipient’s immune system. Its lead ALG-115 program is advancing through preclinical and IND-enabling work for lung transplantation. Allogenetics is developing a one-time ex vivo gene therapy that modifies donor organs before transplantation, aiming to reduce immune rejection without suppressing the recipient’s immune system. Its lead ALG-115 program is advancing through preclinical and IND-enabling work for lung transplantation. | €3.8M | Pre-Series ASeries A | Biotech | Germany | Investors | |
| TT TwoStep TherapeuticsCompany profile A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors. A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors. | $62.5M | Series A | Biotech | United States | Investors | |
| PI Pixeom, Inc.Company profile A biotechnology startup developing numerical representations of three-dimensional molecules for AI-assisted drug and chemical research. A biotechnology startup developing numerical representations of three-dimensional molecules for AI-assisted drug and chemical research. | Undisclosed | Seed | Biotech | Japan | Investors | |
| SO Solstice OncologyCompany profile A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment. A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment. | $225M | Series A | Biotech | United States | Investors | |
| VB ViaNautis BioCompany profile A non-viral nanovesicle platform targets delivery of genetic medicines to specific cells and tissues. A non-viral nanovesicle platform targets delivery of genetic medicines to specific cells and tissues. | Undisclosed | InvestmentUndisclosed | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 28, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.